TickerFacts.

Tonix Pharmaceuticals Holding Corp. (TNXP): Cost of Revenue

Annual figures by period end, from SEC filings.

$6.64M
Year ended 2025-12-31
$4.71M
Trailing 12 months to 2026-06-30
$7.76M2023-12-31: $4.74M2024-12-31: $7.76M2025-12-31: $6.64M$6.64M
2023-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$6.64M-14.5%2026-03-12, From 2025-01-01
2024-12-31$7.76M+63.8%2026-03-12, From 2024-01-01
2023-12-31$4.74Mn/a2025-03-18, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$6.64M-14.5%
CV Sciences, Inc. (CVSI)2025-12-31$7.04M-17.6%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$857.0K-28.6%
Pyxis Oncology, Inc. (PYXS)2025-12-31$2.39M+402.7%
Jaguar Health, Inc. (JAGX)2025-12-31$3.77M+93.0%
uniQure N.V. (QURE)2025-12-31$1.69M+33.1%
International Stem Cell Corp (ISCO)2025-12-31$4.03M+7.1%
Evofem Biosciences, Inc. (EVFM)2025-12-31$4.62M+20.4%
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31$10.64M-38.8%

Compare TNXP, CVSI, EMMA, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗